Compare · CMPI vs CSL
CMPI vs CSL
Side-by-side comparison of Checkmate Pharmaceuticals Inc. (CMPI) and Carlisle Companies Incorporated (CSL): market cap, price performance, sector, and recent activity on the wire.
Summary
- CMPI operates in Consumer Durables, while CSL operates in Industrials - the two are in different parts of the market.
- CSL is the larger of the two at $13.32B, about 281.3x CMPI ($47.4M).
- CSL has hit the wire 1 time in the past 4 weeks while CMPI has been quiet.
- CSL has more recent analyst coverage (17 ratings vs 1 for CMPI).
- Company
- Checkmate Pharmaceuticals Inc.
- Carlisle Companies Incorporated
- Price
- $10.49+0.00%
- $334.06-0.33%
- Market cap
- $47.4M
- $13.32B
- 1M return
- -
- +4.18%
- 1Y return
- -
- +3.52%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 1
- Recent ratings
- 1
- 17
Checkmate Pharmaceuticals Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Carlisle Companies Incorporated
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally. It operates through four segments: Carlisle Construction Materials, Carlisle Interconnect Technologies, Carlisle Fluid Technologies, and Carlisle Brake & Friction. The Carlisle Construction Materials segment produces building envelopes for commercial, industrial, and residential buildings, including single-ply roofing products, rigid foam insulations, spray polyurethane foam, architectural metal products, heating, ventilation and air conditioning hardware and sealants, waterproofing products, and air and vapor barrier systems. The Carlisle Interconnect Technologies segment produces wires and cables for the commercial aerospace, military and defense electronics, medical device, industrial, and test and measurement markets. It also offers sensors, connectors, contacts, cable assemblies, complex harnesses, racks, trays, and installation kits, as well as engineering and certification services. The Carlisle Fluid Technologies segment produces engineered liquid products, powder products, sealants and adhesives finishing equipment, and integrated system solutions for spraying, pumping, mixing, metering, and curing of coatings used in the automotive manufacture, general industrial, protective coating, wood, and specialty and automotive refinishing markets. The Carlisle Brake & Friction segment provides duty brakes, and clutch and transmission products for the construction, agriculture, mining, aircraft, on-highway, and other industrial markets. The company sells its products under the Carlisle, Binks, DeVilbiss, Ransburg, BGK, MS Powder, Hawk, Wellman, Thermax, Tri-Star, LHi Technology, Providien, SynTec, Weatherbond, Hunter Panels, Resitrix, Hertalan, Insulfoam, and Velvetouch brands. Carlisle Companies Incorporated was founded in 1917 and is headquartered in Scottsdale, Arizona.
Latest CMPI
- Axonis Therapeutics Announces $115 Million Series A Financing
- venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
- SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D filed by Checkmate Pharmaceuticals Inc.
- SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.
- Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers $2.5M Milestone Payment to XOMA
- SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.
Latest CSL
- Carlisle Companies to Announce Third Quarter 2026 Results on October 28, 2026
- Director Singh Jesse G converted options into 4,070 shares and returned 505 shares to the company, increasing direct ownership by 76% to 8,247 units (SEC Form 4)
- SEC Form 4 filed by Director Palmer Sheryl
- Director Frias James D acquired $64,959 worth of shares (197 units at $329.74), increasing direct ownership by 4% to 5,723 units (SEC Form 4)
- Director Ricard Corrine D. acquired $64,959 worth of shares (197 units at $329.74), increasing direct ownership by 3% to 6,015 units (SEC Form 4)
- Carlisle Companies Incorporated filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Director Frias James D
- SEC Form 4 filed by Director Hansen Maia
- SEC Form 4 filed by Director Ricard Corrine D.
- SEC Form 4 filed by Director Singh Jesse G